tbuckley/cabot-search huggingface dataset:
Human Rabies Immune Globulin
Authors: Robert H. Rubin
Journal: JAMA (1973)

Human-derived rabies immune globulin (HRIG) was administered intramuscularly to 24 male volunteers according to two dose schedules: either 20 ml (equivalent to the World Health Organization [WHO] recommendation of 40 internation units/kg for equine-derived antiserum) or one-fourth of the WHO recommendation (10 IU/kg). The 10-IU/kg dose gave barely detectable antirabies antibody titers and is not considered of therapeutic value. The 20-ml dose gave higher, longer lasting titers of antirabies antibody than the comparable doses of equine antiserum currently in use. There were no untoward reactions. Before administration of HRIG, all 24 volunteers had IgG class anti-IgG antibodies (mean titer, 114μg/ml); 22 of 24 had IgA class anti-IgG antibodies (mean titer, 65μg/ml); and none of the 24 had IgM class anti-IgG antibodies. Administration of HRIG caused no significant change in these titers.
Macrophage Damage in Relation to the Pathogenesis of Lung Diseases
Authors: Joseph D. Brain
Journal: Environmental Health Perspectives (1980)

Pulmonary macrophages are important since their migratory patterns and behavior are often pivotal events in the pathogenesis of pulmonary disease. Alveolar macrophages act to decrease the probability of particle penetration through epithelial barriers, and their phagocytic and lytic potentials provide most of the known bactericadal properties of the lung. Macrophages are also involved in immune responses and in defense against neoplasms. Increased inert or infectious particles stimulate the recruitment of additional macrophages. Most free cells containing particles eventually reach the airways and are quickly carried to the pharynx and swallowed. In addition, evidence has now accumulated that macrophages play a part in the pathogenesis of pulmonary diseases. For example, the ingestion of some particles by macrophages causes a release of lysosomal enzymes into the macrophage cytoplasm. These enzymes may kill the macrophage, and dead or dying macrophages release a substance with attracts fibroblasts that elicit fibrogenic responses. Other toxic particles, such as cigarette smoke, my lead to a release of proteases and other toxic enzymes. All particles are capable of competitive inhibition of phagocytosis in macrophages and many may be cytotoxic and further depress phagocytosis. In addition, connective tissue macrophages may contribute to lung disease by concentrating and storing potent carcinogens or other toxic particles close to a reactive bronchial epithelium for long periods. Thus, even through macrophages serve as a first line of defense for the alveolar surface, they may also be capable of injuring the host while exercising their defensive role.
Effects of Changes in Calmodulin Levels on Cell Proliferation
Authors: Colin D. Rasmusen, Anthony R. Means
Journal: Environmental Health Perspectives (1990)

Calmodulin (CaM) is one of several proteins regulated in a cell cycle-dependent manner. CaM is synthesized at the G1/S boundary and has been implicated in the regulation of cell cycle progression. To elucidate the role of calmodulin in cell cycle control, clonal mouse C127 cell lines transformed with one of four different bovine papilloma virus (BPV)-based vectors were studied. These vectors express a) a chicken CaM gene regulated by its own promoter (CM cells), b) the chicken CaM gene regulated by the inducible human metallothionein-IIa promoter (MCM cells), c) CaM antisense RNA using the Zn2+ inducible mouse metallothionein-I (mMT-I) promoter (AS cells), or d) a rat parvalbumin gene using the chicken CaM promoter (PV cells). C127 cells transformed by BPV-1 alone (BPV cells) are used as a control in each case. Previous studies showed that a 4-fold increase in CaM levels in CM cells shortened the cell cycle by reducing the length of the G1 period. Expression of parvalbumin in PV cells has no effect on cell cycle length, suggesting that increased CAM, and not simply increased Ca2(+)-binding protein, accelerates proliferation. Zn2(+)-induced expression of the chicken CaM gene in MCM cells increased the rate of proliferation, while Zn2(+)-induced expression of high levels of CaM anti-sense RNA stops proliferation at Zn2+ levels that do not affect the growth of BPV cells. In CM cells increased CaM affects cell cycle-dependent level of mRNAs for tubulin, vimentin, and c-myc relative to the levels in BPV cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Doctor Therne.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Addition to Report of College of Physicians
Journal: BMJ (1841)

The Royal College of Surgeons of Edinburglh havitng transmitted a report on the proposed measure of AMedical Reform to the Roval College of Surgeons in Ireland, with4 a requiest that it should be considered, and if approved of; that the two colleges should cooperate to attain the ohject § contemplated-tlhe subject was referred to a commi ttee.''Ihis comniittee presented their report last week, recoin- mending that the college shQW4l unite with the college of Edinburgh in their efforts, and that the bill of Mr. War- buirton, with certain modifications, and certain portions of AMr.Ilawes's draft, should be suipported."
Tyroid Crisis and the Law
Authors: Bernard J. Ficarra
Journal: JAMA (1969)

<h3>To the Editor:—</h3> In response to the comment: "It is perfectly true that the possibility of a thyroid crisis is something which should not be neglected in every patient who has thyroid therapy. Its occurrence is exceedingly rare, however, when the patient has been properly prepared for surgery by the preoperative administration of iodine," permit me to state that Dr. Ryan and I were members of the house staff at the same time (1939-1941) at Kings County Hospital Center in Brooklyn, NY. At that time Kings County Hospital had the largest thyroid surgical service of any municipal hospital in the United States. It was one of two thyroid residencies approved for certification by the American Board of Surgery. As a house officer on this thyroid service many instances of postthyroidectomy crises were seen and recorded. All were treated prior to surgery with strong iodine solution according to the method of
DISINFECTION CIRCULAR.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Streptokinase
Authors: Sol Sherry
Journal: New England Journal of Medicine (1969)

LIKE urokinase, which is now undergoing evaluation as a therapeutic agent in the National Heart Institute's Urokinase-Pulmonary Embolism Trial (a multi-institutional controlled study initiated in October, 1968) and whose developmental background was reviewed in a recent editorial in the Journal,1 streptokinase is an activator of the naturally occurring human fibrinolytic enzyme system. This streptococcal secretory protein has been available for study for many years and was developed for thrombolytic purposes in the United States, where it served as a model for establishing the scientific base and therapeutic potential for the use of activators of the fibrinolytic system.2 , 3 The investigation . . .
911. C-Terminal Truncated Microdystrophin Recruits Dystrobrevin and Syntrophin to the Dystrophin-Associated Glycoprotein Complex and Reduces Muscular Dystrophy in Symptomatic Utrophin/Dystrophin Double Knock-Out Mice
Authors: Yongping Yue, Mingju Liu, Dongsheng Duan
Journal: Molecular Therapy (2006)

C-terminal truncated (ΔC) microdystrophin is being developed for Duchenne muscular dystrophy (DMD) gene therapy. Encouraging results have been achieved in the mdx mouse model. Unfortunately, mdx mice do not display the same phenotype as human patients. Evaluating ΔC microdystrophin in a symptomatic model will be of significant relevance to human trial. Utrophin/ dystrophin double knock-out (u-dko) mice were developed to mold severe dystrophic changes in human patients. In this study we evaluated therapeutic effect of the ΔR4-R23/ΔC microdystrophin gene (ΔR4/ΔC) after serotype-6 adeno-associated virus (AAV-6)- mediated gene transfer in neonatal u-dko muscle. At two months after gene transfer, percentage of centrally nucleated myofiber was reduced from 89.2% to 3.4% and muscle weight was normalized. Furthermore, we have demonstrated for the first time that ΔC microdystrophin can eliminate interstitial fibrosis, macrophage infiltration and restore dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex. Interestingly neuronal nitric oxide synthase was not restored. The most impressive results were achieved in muscle force measurement. Neonatal gene therapy increased twitch and tetanic specific force. It also brought the response to eccentric contraction-induced injury to the normal range. In summary, our results suggest that the ΔR4/ΔC microgene holds great promise in preventing muscular dystrophy.
Alcohol and fatal injuries among US adults. Findings from the NHANES I Epidemiologic Follow-up Study
Authors: R. F. Anda
Journal: JAMA (1988)

Use of alcohol is an important risk factor for fatal injuries. However, little information on the relationship between self-reported alcohol use and subsequent risk of fatal injury is available. Therefore, we examined the relationship between the usual number of drinks consumed per occasion and the incidence of fatal injuries in a cohort of US adults. Using data on self-reported alcohol use obtained from 13 251 adults who were included in the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study (mean length of follow-up, 9.3 years), we calculated the incidence of fatal injury according to the usual number of drinks consumed per occasion. After we adjusted for the effects of age, sex, race, and education, persons who consumed five or more drinks per occasion were nearly twice as likely to die from injuries (relative risk, 1.9; 95% confidence interval, 1.0 to 3.5) than persons who drank fewer than five drinks per occasion. A dose-response relationship was observed between the usual number of drinks consumed per occasion and risk of fatal injury, with persons who reported drinking nine or more drinks per occasion being 3.3 times more likely to die from injuries (95% confidence interval, 1.3 to 8.3). These data demonstrate the impact of alcohol use on mortality from injuries in the United States and suggest that self-reported alcohol consumption is an important indicator of risk for fatal injury. (<i>JAMA</i>1988;260:2529-2532)
Healthy People 2000 at mid decade
Authors: J. M. McGinnis
Journal: JAMA (1995)

THE nation's health goals for the year 2000 were set forth with the 1990 release of<i>Healthy People 2000</i>,<sup>1</sup>which reviewed the principal health challenges for Americans and identified in measurable terms the opportunities for health gains during the 1990s. The arrival of the decade's midpoint prompts an assessment of progress to date. For editorial comment see p 1149. <i>Healthy People 2000</i>was based on the previous experience with setting national health targets for the year 1990,<sup>2,3</sup>the results for which have been described elsewhere.<sup>4</sup>The targets contained in<i>Healthy People 2000</i>were developed between 1987 and 1990 through an extensive consultative and hearings process conducted and managed by the US Public Health Service (PHS) in partnership with the National Academy of Sciences' Institute of Medicine.<sup>5</sup>To provide guidance to the effort, a national consortium was formed that included the principal health officials of the 50
Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)
Authors: G. Pusole, M. Puzzoni, R. Mascia, L. Demurtas, A. Dessì, A. Cubeddu, E. Lai, S. Tolu, P. Ziranu, L. Orgiano, V. Pusceddu, G. Astara, C. Madeddu, E. Massa, L. Casula, G. Palmieri, M. Scartozzi
Journal: Annals of Oncology (2016)
Hypertension and Nephritis.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Blood, New York
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Platelet-suppressant therapy in patients with coronary artery disease
Authors: P. Steele
Journal: JAMA (1978)

Platelets may contribute to the pathogenesis of atherosclerosis and to the complications of coronary atherosclerosis, acute myocardial infarction, unstable angina, and sudden cardiac death. In addition, platelets may contribute to saphenous vein aortocoronary graft occlusion. Of 104 men with coronary artery disease, platelet survival (SURV) (chromium<sup>51</sup>labeling) was shortened in 68% (3.1±0.03 days [average±SEM]; normal, 3.7±0.03 days;<i>P</i>&lt;.001). Three platelet-suppressant drugs, sulfinpyrazone, clofibrate, and dipyridamole increased SURV. Saphenous vein graft occlusion was associated with shortened SURV. Of 36 men with occlusion of at least one graft, SURV was shortened in 35 (2.5±0.08 days), whereas in 19 with all grafts open, SURV was shortened in six (3.5±0.10 days;<i>P</i>&lt;.001). These drugs increased SURV (2.3±0.08 to 2.7±0.11 days;<i>P</i>&lt;.01) and were associated with improved graft patency (four of 32 grafts after initial bypass vs 30 of 34 grafts open after second operation). (<i>JAMA</i>240:228-231, 1978)
Commentaire de travail de A. Hoffman et al., pp. 827
Journal: Endoscopy (2010)

See also: High definition colonoscopy combined with i-Scan is superior in the detection of colorectal neoplasias compared with standard video colonoscopy: a prospective randomized controlled trialEndoscopy 2010; 42(10): 827-833DOI: 10.1055/s-0030-1255713
Strategies for the review of transfusion practices
Authors: L. E. Silberstein
Journal: JAMA (1989)

WITH the increased awareness of transfusion-associated human immunodeficiency virus infection, blood transfusion therapy has become an issue of increasing concern to both the general public and to health practitioners. Several measures have already been instituted to reduce the risk of transfusion-related infections: (1) improved screening procedures, (2) early detection of infectious donors by serological methods, (3) institution of confidential donor self-deferral, and (4) inactivation of viruses in some blood products with solvents and detergents. Although these measures have improved the quality of the blood supply, several important issues, such as other medical complications of blood transfusions, the conservation of limited resources, and cost, remain. Consequently, hospital transfusion committees have been widely used as one mechanism of monitoring blood use by peer review. The Joint Commission on Accreditation of Healthcare Organizations, in Chicago, Ill, has emphasized that the intent of blood use review is, in addition to monitoring transfusion activity, to also
OBSCURE FORMS OF SUBACUTE COR PULMONALE
Authors: M. C. P.
Journal: Annals of Internal Medicine (1939)

Editorial1 November 1939OBSCURE FORMS OF SUBACUTE COR PULMONALEM. C. P.M. C. P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-13-5-899 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDuring recent years in which clinicians in the United States have become interested in the syndrome of right heart failure, the causes of increased resistance to the pulmonary circulation have been restudied. The problem is a fascinating one because we possess as yet no direct method of measuring the pressures in the pulmonic arteries or veins and must proceed largely through indirect means.Our basic information we owe to the postmortem observations of disproportionate hypertrophy and dilatation of the right ventricle in certain lesions of the lungs which would apparently entail a diminution in the pulmonary vascular bed; for example,...1 BRENNER O: Pathology of the vessels of the pulmonary circulation. Part IV, Arch. Int. Med., 1935, lvi, 976. CrossrefGoogle Scholar2 BRENNER O: Pathology of the vessels of the pulmonary circulation. Part V, Arch. Int. Med., 1935, lvi, 1189. CrossrefGoogle Scholar3 KARSNER HT: Sclerosis of the pulmonary arteries, Chapter XVI in "Arteriosclerosis" (edited by EDMUND V. COWDRY, PH.D.), 1933, The Macmillan Company, New York, p. 457. Google Scholar4 FOWLER WM: Obliterating thrombosis of the pulmonary arteries, ANN. INT. MED., 1934, vii, 1101. Google Scholar5 JARCHO S: Diffusely infiltrative carcinoma. A hitherto undescribed correlation of several varieties of tumor metastasis, Arch. Path., 1936, xxii, 674. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1939Volume 13, Issue 5Page: 899-901KeywordsArteriesHeart failureLesionsLungsRight ventricleVeins ePublished: 1 December 2008 Issue Published: 1 November 1939 PDF downloadLoading ...
Tracheobronchial studies via transcricothyroid approach
Authors: H. Chamorro
Journal: JAMA (1974)

Cytological studies have proven very helpful in the evaluation of conditions in patients with small and solitary bronchogenic carcinomas. The use of the transcricothyroid approach for combined examinations has proven satisfactory in a series of 600 patients, 200 of whom had brush biopsies with retrieval of enough tissue material to warrant cytological diagnosis. The use of the transcricothyroid approach for all studies has been less traumatic and accepted by patients more readily than the conventional transnasal and transoral routes.
PRIMARY SARCOMA OF THE LOWER LIP A. J. MARKLEY, M.D. DENVER
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal